142 related articles for article (PubMed ID: 23592368)
1. Pharmacokinetic/pharmacodynamic modeling of 5-fluorouracil by using a biomarker to predict tumor growth in a rat model of colorectal cancer.
Kobuchi S; Ito Y; Okada K; Imoto K; Kuwano S; Takada K
J Pharm Sci; 2013 Jun; 102(6):2056-2067. PubMed ID: 23592368
[TBL] [Abstract][Full Text] [Related]
2. Pre-therapeutic assessment of plasma dihydrouracil/uracil ratio for predicting the pharmacokinetic parameters of 5-fluorouracil and tumor growth in a rat model of colorectal cancer.
Kobuchi S; Ito Y; Okada K; Imoto K; Kuwano S; Takada K
Biol Pharm Bull; 2013; 36(6):907-16. PubMed ID: 23575271
[TBL] [Abstract][Full Text] [Related]
3. A predictive biomarker for altered 5-fluorouracil pharmacokinetics following repeated administration in a rat model of colorectal cancer.
Kobuchi S; Kuwano S; Imoto K; Okada K; Nishimura A; Ito Y; Shibata N; Takada K
Biopharm Drug Dispos; 2013 Oct; 34(7):365-76. PubMed ID: 23836081
[TBL] [Abstract][Full Text] [Related]
4. Association between the pharmacokinetics of capecitabine and the plasma dihydrouracil to uracil ratio in rat: A surrogate biomarker for dihydropyrimidine dehydrogenase activity.
Kobuchi S; Akutagawa M; Ito Y; Sakaeda T
Biopharm Drug Dispos; 2019 Jan; 40(1):44-48. PubMed ID: 30592773
[TBL] [Abstract][Full Text] [Related]
5. The dihydrouracil/uracil ratio in plasma, clinical and genetic analysis for screening of dihydropyrimidine dehydrogenase deficiency in colorectal cancer patients treated with 5-fluorouracil.
Ben Fredj R; Gross E; Ben Ahmed S; Hassine H; Saguem S
Pathol Biol (Paris); 2009 Sep; 57(6):470-6. PubMed ID: 18619742
[TBL] [Abstract][Full Text] [Related]
6. Correlation between the urinary dihydrouracil-uracil ratio and the 5-FU plasma concentration in patients treated with oral 5-FU analogs.
Nakayama Y; Matsumoto K; Inoue Y; Katsuki T; Kadowaki K; Shibao K; Tsurudome Y; Hirata K; Sako T; Nagata N; Itoh H
Anticancer Res; 2006; 26(5B):3983-8. PubMed ID: 17094430
[TBL] [Abstract][Full Text] [Related]
7. A simple and rapid high-performance liquid chromatographic (HPLC) method for 5-fluorouracil (5-FU) assay in plasma and possible detection of patients with impaired dihydropyrimidine dehydrogenase (DPD) activity.
Ciccolini J; Mercier C; Blachon MF; Favre R; Durand A; Lacarelle B
J Clin Pharm Ther; 2004 Aug; 29(4):307-15. PubMed ID: 15271097
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of 5-fluorouracil and increased hepatic dihydropyrimidine dehydrogenase activity levels in 1,2-dimethylhydrazine-induced colorectal cancer model rats.
Kobuchi S; Ito Y; Okada K; Imoto K; Takada K
Eur J Drug Metab Pharmacokinet; 2013 Sep; 38(3):171-81. PubMed ID: 23197286
[TBL] [Abstract][Full Text] [Related]
9. Circadian rhythm of dihydrouracil/uracil ratios in biological fluids: a potential biomarker for dihydropyrimidine dehydrogenase levels.
Jiang H; Lu J; Ji J
Br J Pharmacol; 2004 Feb; 141(4):616-23. PubMed ID: 14744810
[TBL] [Abstract][Full Text] [Related]
10. Effects of a bolus injection of 5-fluorouracil on dihydropyrimidine dehydrogenase activity in rats receiving continuous infusion of 5-fluorouracil.
Kobuchi S; Hayashi A; Taniguchi M; Ito Y; Tamura T; Sakaeda T
Cancer Chemother Pharmacol; 2016 Sep; 78(3):517-23. PubMed ID: 27417318
[TBL] [Abstract][Full Text] [Related]
11. Predicting 5-fluorouracil toxicity: DPD genotype and 5,6-dihydrouracil:uracil ratio.
Sistonen J; Büchel B; Froehlich TK; Kummer D; Fontana S; Joerger M; van Kuilenburg AB; Largiadèr CR
Pharmacogenomics; 2014 Sep; 15(13):1653-66. PubMed ID: 25410891
[TBL] [Abstract][Full Text] [Related]
12. 5-Fluorouracil Response Prediction and Blood Level-Guided Therapy in Oncology: Existing Evidence Fundamentally Supports Instigation.
Chavani O
Ther Drug Monit; 2020 Oct; 42(5):660-664. PubMed ID: 32649488
[TBL] [Abstract][Full Text] [Related]
13. Pretherapeutic uracil and dihydrouracil levels in saliva of colorectal cancer patients are associated with toxicity during adjuvant 5-fluorouracil-based chemotherapy.
Carlsson G; Odin E; Gustavsson B; Wettergren Y
Cancer Chemother Pharmacol; 2014 Oct; 74(4):757-63. PubMed ID: 25102934
[TBL] [Abstract][Full Text] [Related]
14. LC-MS/MS method for simultaneous analysis of uracil, 5,6-dihydrouracil, 5-fluorouracil and 5-fluoro-5,6-dihydrouracil in human plasma for therapeutic drug monitoring and toxicity prediction in cancer patients.
Büchel B; Rhyn P; Schürch S; Bühr C; Amstutz U; Largiadèr CR
Biomed Chromatogr; 2013 Jan; 27(1):7-16. PubMed ID: 22454320
[TBL] [Abstract][Full Text] [Related]
15. Indirect assessment of dihydropyrimidine dehydrogenase activity in cats.
Saba CF; Schmiedt CW; Freeman KG; Edwards GL
Vet Comp Oncol; 2013 Dec; 11(4):265-71. PubMed ID: 24007333
[TBL] [Abstract][Full Text] [Related]
16. The dihydrouracil/uracil ratios in plasma and toxicities of 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer patients.
Zhou ZW; Wang GQ; Wan de S; Lu ZH; Chen YB; Li S; Chen G; Pan ZZ
Chemotherapy; 2007; 53(2):127-31. PubMed ID: 17308379
[TBL] [Abstract][Full Text] [Related]
17. DPD functional tests in plasma, fresh saliva and dried saliva samples as predictors of 5-fluorouracil exposure and occurrence of drug-related severe toxicity.
Neto OV; Raymundo S; Franzoi MA; do Carmo Artmann A; Tegner M; Müller VV; Hahn RZ; Alves GV; Schwartsmann G; Linden R; Antunes MV
Clin Biochem; 2018 Jun; 56():18-25. PubMed ID: 29625079
[TBL] [Abstract][Full Text] [Related]
18. Pretherapeutic uracil and dihydrouracil levels of colorectal cancer patients are associated with sex and toxic side effects during adjuvant 5-fluorouracil-based chemotherapy.
Wettergren Y; Carlsson G; Odin E; Gustavsson B
Cancer; 2012 Jun; 118(11):2935-43. PubMed ID: 22020693
[TBL] [Abstract][Full Text] [Related]
19. Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage.
Gamelin E; Boisdron-Celle M; Guérin-Meyer V; Delva R; Lortholary A; Genevieve F; Larra F; Ifrah N; Robert J
J Clin Oncol; 1999 Apr; 17(4):1105. PubMed ID: 10561167
[TBL] [Abstract][Full Text] [Related]
20. The value of dihydrouracil/uracil plasma ratios in predicting 5-fluorouracil-related toxicity in colorectal cancer patients.
Kristensen MH; Pedersen P; Mejer J
J Int Med Res; 2010; 38(4):1313-23. PubMed ID: 20926004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
